WAYNE, Pa., Aug. 1, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/tsrx) is investigating potential claims against the board of directors of Trius Therapeutics, Inc. ("Trius" or the "Company") (NASDAQ: TSRX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Cubist Pharmaceuticals, Inc. in a deal valued at approximately $818 million.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Trius for not acting in the Company's shareholders' best interests in connection with the sale process. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at email@example.com or visit: www.rmclasslaw.com/cases/tsrx.
Under the terms of the proposed transaction, Trius's stockholders will receive $13.50 for each share of Trius common stock they own. In addition to the cash consideration, Trius shareholders will receive a Contingent Value Right worth an additional $2 per share in cash that is not publicly tradable.
If you own shares of Trius and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/tsrx. You may also email Mr. Maniskas at firstname.lastname@example.org. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
SOURCE Ryan & Maniskas, LLP